Actuate Therapeutics (ACTU) Change in Account Payables (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Change in Account Payables of $185555.0 for Q4 2025, up 161.26% year-over-year from $71023.5 in Q4 2024, and up 110.15% quarter-over-quarter from -$1.8 million in Q3 2025.
Actuate Therapeutics (ACTU) Change in Account Payables (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Change in Account Payables for 3 consecutive years, with $185555.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 161.26% year-over-year to $185555.0; the TTM figure through Dec 2025 stood at -$512536.0 (up 65.85% YoY), while the FY2025 annual figure was -$512536.0, up 65.85% from the prior year.
- Change in Account Payables climbed to $185555.0 in Q4 2025 per ACTU's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.9 million in Q2 2024 and bottomed at -$3.6 million in Q3 2024.
- Historically, Change in Account Payables has averaged -$92901.7 across 3 years, with a median of $351595.0 in 2023.
- Annual changes were most pronounced in 2024 — Change in Account Payables slumped 1744.84% — and 2025, when it jumped 161.26%.
- Actuate Therapeutics' Change in Account Payables stood at $864683.0 in 2023, then tumbled by 135.03% to -$302904.0 in 2024, then surged by 161.26% to $185555.0 in 2025.
- Business Quant data shows ACTU's Change in Account Payables at $185555.0 in Q4 2025, -$1.8 million in Q3 2025, and $507954.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 185,555.00 |
| Dec 31, 2025 | 185,555.00 |
| Sep 30, 2025 | -1.83 Mn |
| Sep 30, 2025 | -1.83 Mn |
| Jun 30, 2025 | 507,954.00 |
| Jun 30, 2025 | 507,954.00 |
| Mar 31, 2025 | 622,162.00 |
| Mar 31, 2025 | 622,162.00 |
| Dec 31, 2024 | -302,904.00 |
| Dec 31, 2024 | -302,904.00 |
| Sep 30, 2024 | -3.61 Mn |
| Sep 30, 2024 | -3.61 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 483,703.00 |
| Mar 31, 2024 | 483,703.00 |
| Dec 31, 2023 | 864,683.00 |
| Dec 31, 2023 | 864,683.00 |
| Sep 30, 2023 | 219,487.00 |
| Sep 30, 2023 | 219,487.00 |